4D Molecular reports positive 2-year Phase 2b data for 4D-150 in wet AMD; 78% treatment burden reduction

4D Molecular Therapeutics, Inc.

Overall cohort: 78% reduction in treatment burden (2.7 mean supplemental injections vs 12.0 projected for aflibercept Q8W).
Recently diagnosed subgroup: 87% reduction (1.6 mean supplemental injections vs 12.0).
Dose response maintained in favor of Phase 3 dose (3E10 vg/eye) over 2 years.
Safety: 2.8% (2/71) had transient mild IOI within first 28 weeks; no new inflammation with up to 4+ years follow-up.
No 4D-150-related hypotony, endophthalmitis, vasculitis, or choroidal effusions observed.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.